At the cellular level, the loss of SCN4B/β4 in cancer cells further stimulates their invasiveness by favouring amoeboid migration, supported by the overactivation of the RhoA pathway, yet keeping the ECM-degradative activity intact. Here, SCN4B is linked to cancer.